Bazedoxifene/conjugated estrogens

Bazedoxifene/conjugated estrogens
Combination of
Bazedoxifene Selective estrogen receptor modulator
Conjugated estrogens Conjugated estrogens
Clinical data
Trade names Duavee
Routes of
ATC code G03CC07 (WHO)
Legal status
Legal status
ChemSpider none

The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis. It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer.

Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet. Pfizer expects the drug to become available in the first quarter of 2014.[1]


This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.